IndustryCompany release
Evaxion refocuses on cancer vaccines as EVX-04 heads toward phase 1 filing
Evaxion · Thu 19 Nov 2026
The Nasdaq-listed company is narrowing its pipeline to immuno-oncology, reporting a $3.5M third-quarter net loss and a cash runway stretching toward the end of 2027.
Evaxion (NASDAQ: EVAX) announced on 19 November 2026 that it is shifting its strategy towards immuno-oncology. The company will concentrate on three cancer vaccine candidates: the personalised vaccine EVX-01 for melanoma, and the off-the-shelf vaccines EVX-04 for acute myeloid leukaemia (AML) and EVX-05.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Company's press release: Evaxion ↗
Article written by VigiEye from the official source (Evaxion). Claims are the company's own. AI-assisted; check the source before acting.
More Industry
All →
CytoSorbents reaches operating cash flow breakeven in Q3 as operating loss narrows 59%
🇺🇸 Cytosorbents Corp (CTSO) · Thu 19 Nov 2026
Emmaus Q3 revenue falls to $1.9M after Endari licence; going-concern doubt flagged
🇺🇸 Emmaus Life Sciences, Inc. (EMMA) · Thu 19 Nov 2026
Prenetics widens H2 EBITDA loss guidance to $30-35M as IM8 spending rises
Prenetics Global Ltd (PRE) · Wed 18 Nov 2026
Quantum-Si detects all 20 amino acids at single-molecule level on Proteus platform
🇺🇸 Quantum-Si Inc (QSI) · Wed 18 Nov 2026
NeOnc to meet FDA in January 2027 on NEO100 accelerated approval path
🇺🇸 Neonc Technologies Holdings, Inc. (NTHI) · Wed 18 Nov 2026
newcleo reports Q3 revenue of about €10M and €233.4M cash as PRECURSOR e-core completed
newcleo plc (NWCL) · Wed 18 Nov 2026